Puma Biotechnology, Inc. is a biopharmaceutical company. The company is headquartered in Los Angeles, California and currently employs 172 full-time employees. The company went IPO on 2012-03-21. The firm is commercializing NERLYNX, an oral version of neratinib, for the treatment of certain HER2-positive breast cancers. NERLYNX is approved in the United States for two indications: the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer following adjuvant trastuzumab-based therapy and for use in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. The firm has in-licensed and is responsible for the global development and commercialization of alisertib. The company intends to pursue the development of alisertib initially in small cell lung cancer and hormone receptor positive breast cancer.
Follow-Up Questions
What is Puma Biotechnology Inc (PBYI)'s P/E Ratio?
The P/E ratio of Puma Biotechnology Inc is 8.8088
Who is the CEO of Puma Biotechnology Inc?
Mr. Alan Auerbach is the Chairman of the Board of Puma Biotechnology Inc, joining the firm since 2010.
What is the price performance of PBYI stock?
The current price of PBYI is $5, it has increased 2.14% in the last trading day.
What are the primary business themes or industries for Puma Biotechnology Inc?
Puma Biotechnology Inc belongs to Biotechnology industry and the sector is Health Care
What is Puma Biotechnology Inc market cap?
Puma Biotechnology Inc's current market cap is $252.1M
Is Puma Biotechnology Inc a buy, sell, or hold?
According to wall street analysts, 5 analysts have made analyst ratings for Puma Biotechnology Inc, including 0 strong buy, 1 buy, 3 hold, 2 sell, and 0 strong sell
